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However, the potential existence of off-
target effects of the inhibitor must be
considered when interpreting these
findings.
The current study raises several impor-
tant questions regarding DN PPAR-Y
mutations. Do the alterations observed
by the authors also apply to the small
arteries that play the major role in regu-
lating vascular resistance in the peripheral
circulation (either uniformly, or in crucial
vascular beds such as the kidney and
brain) (see Beyer et al., 2008)? What is
the relative importance of smooth muscle
(Pelham et al., 2012) versus endothelial
(Beyer et al., 2008) expression of PPAR-Y
mutations in determining the ultimate
phenotype in intact blood vessels? How
does the mutation affect other crucial
end points in cardiovascular disease,
e.g., end organ damage, blood-flow
regulation, and responses to circulatory
stress? Finally, what are the exact mech-
anisms responsible for the chronically
elevated blood pressure in the mice
carrying the DN mutation of PPAR-Y?Nonetheless, this study provides
valuable insight into the possible mecha-
nisms by which dominant negative muta-
tions in PPAR-Y may lead to altered
vascular reactivity and elevated blood
pressure. From a vascular biology stand-
point, the finding of a substantial vascular
alteration that is independent of oxidant
stress and NO availability is especially
interesting and worthy of further investi-
gation. The results also have important
clinical implications, as some patients
presenting with early onset hyperten-
sion and insulin resistance carry muta-
tions in the PPAR-Y ligand-binding
domain, which leads to dominant nega-
tive activity (Barroso et al., 1999; Savage
et al., 2003). Furthermore, activation of
PPAR-Y by thiazolidinedione insulin-
sensitizing drugs such as rosiglitazone
attenuates the development of hyperten-
sion and inhibits atherosclerosis in
patients with type II diabetes, but the
mechanisms mediating the vascular
effects of PPAR-Y are poorly understood.
Because these commonly used drugs
have a number of serious side effectsCell Metabolism 1(Graham et al., 2010), it is evident that
a greater understanding of this pathway
will be required to provide appropriate
drug targets.REFERENCES
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Distinctive metabolism associated with particular cell states is increasingly being defined in normal and
malignant cells. Ito et al. (2012) now show that fatty acid oxidation is associated with hematopoietic stem
cells and determines whether they undergo symmetric or asymmetric cell division, driving a fundamental
property of the stem cell state.Increased attention to the metabolism of
malignant cells has raised the issue of
just how different they are from their
normal counterparts. This is particularly
of interest in the context of cell functions
such as self-renewal, shared by both
malignant cells and normal stem cells.
Whether the process of self-renewal has
distinct metabolic requirements in cancerand normal cells is unclear, but is of
potential consequence as therapies tar-
geting cancer cell metabolism move
toward the clinic. Work by the Pandolfi
laboratory now adds a new topic for
consideration in this rapidly evolving field.
Ito et al. show that fatty acid metabolism
is central to a signature feature of hemato-
poietic and other tissue stem cells, the‘‘decision’’ between self-renewal and
differentiation (Ito et al., 2012).
The metabolism of hematopoietic stem
and progenitor cells (HSPCs) has gener-
ally been studied with a focus on the
relative importance of glycolysis versus
oxidative phosphorylation. HSPCs are
known to depend upon HIF-1a, for
example, and while this gene has many6, October 3, 2012 ª2012 Elsevier Inc. 411
Figure 1. Fatty Acid Oxidation Maintains Asymmetric HSC Division
(A) The promyelocytic (PML) gene regulates PPARd to increase fatty acid oxidation (FAO) in hematopoietic
stem cells (HSCs) and biases them toward the fate of asymmetric cell division, leading to continued
maintenance of the HSC pool.
(B) Potential mechanisms by which FAO maintains asymmetric self renewal include (1) shunting of long
chain fatty acids away from lipid and cell membrane synthesis, which is not a major requirement for the
slowly self renewing HSCs; (2) generation of ATP for HSC energy needs; (3) generation of reducing
equivalents for quenching reactive oxygen species (ROS); and (4) generation of acetyl-CoA, chromatin
modification, and preservation of the stem cell epigenome.
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Previewseffects, its role in enforcing glycolysis is
associated with stem cell maintenance
in vivo. Disrupting HIF-1a reduces per-
sistence of the cells upon serial trans-
plantation, a process that depends on
self-renewal (Takubo et al., 2010). HSPCs
have a relatively low mitochondrial mass
per cell, which is consistent with a prefer-
ential use of glycolysis over oxidative
phosphorylation (Simsek et al., 2010).
These characteristics may reflect a
hypoxic environment in which HSPCs
reside, but this remains controversial,
and determinants other than oxygen412 Cell Metabolism 16, October 3, 2012 ª20availability can certainly influence the
relative expression of glycolytic genes.
For example, there are data indicating
that expression of Cripto, a member of
the EGF-CPC family, induces glycolytic
enzyme expression (Miharada et al.,
2011), and other studies suggest that
Meis-1, necessary for HSPC generation,
is responsible for HIF-1a expression in
HSPCs (Simsek et al., 2010). Therefore,
indirect evidence points to HSPCs prefer-
entially undergoing glycolysis through
enhanced expression of glycolytic path-
way genes. It may be logical to consider12 Elsevier Inc.glycolysis central to self-renewal. How-
ever, it has yet to be formally proven.
Indeed, it is not clear that any particular
metabolic pathway is central to stem-
ness in hematopoiesis, although deleting
metabolism-related genes such as
LKB1, TSC, and FOXOs results in pro-
found HSPC phenotypes (Gan et al.,
2008, 2010; Gurumurthy et al., 2010;
Nakada et al., 2010; Tothova et al.,
2007). The work of Ito et al. now provides
the missing direct evidence and does so
by studying a pathway not previously
associated with HSPC function.
Members of the peroxisome prolifera-
tor-activated receptor (PPAR) family of
nuclear receptors are known to be
nutrient sensors and potent transcrip-
tional regulators of enzymes important in
fatty acid transport and fatty acid oxida-
tion (FAO). Manipulating the levels or
activity of PPARd, Ito et al. found that
HSPC function was altered. The deletion
of PPARd led to poor HSPC self renewal
in serial transplantation assays and,
strikingly, a decrease in the ratio of
asymmetric to symmetric divisions of
hematopoietic stem cells. Conversely,
pharmacologic activation of PPARd had
the opposite effect, promoting self-
renewal and increasing asymmetric divi-
sions. These changes in HSPC function
were due to PPARd modification of long-
chain FAO, as the effects were recapitu-
lated by pharmacologic inhibition of
long-chain FAO (Figure 1). Of note, the
effect of FAO inhibition on HSPC was
persistent even with secondary transplan-
tation, suggesting that more than just
metabolite levels were involved.
The hematopoietic stem cell popula-
tion, like many tissue stem cells, is
hypothesized to depend upon the ability
of its daughter cells to undergo either
self-renewal or differentiation with cell
division. Symmetric division, where both
daughter cells either differentiate or self-
renew, is an inexorable path to stem cell
exhaustion or tissue failure from lack
of mature cell replenishment, respec-
tively. Asymmetric stem cell division,
where one daughter cell differentiates
and the other self-renews, is therefore
thought to preserve both the stem cell
and mature cell pools. Shifting between
asymmetric and symmetric division may
enable stem cells to dynamically respond
to changing physiologic needs. Ito et al.
provide evidence that FAO is at the
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Previewscore of this fundamental hematopoietic
property.
Tracking cell surface marker distribu-
tion in daughter cells of dividing HSPCs,
the authors showed that inhibition of
FAO enhanced symmetric, differentiating
cell division, whereas pharmacologic
activation of FAO increased asymmetric
division. Genetic deletion of PML, an
upstream inducer of PPARd (and there-
fore FAO), increased the proportion of
cells expressing a differentiation marker,
suggesting an increase in symmetric,
differentiating divisions in vivo. These
data led to the conclusion that FAO is
critical for stem cells to divide and have
at least one daughter cell self-renew.
Why FAO is critical for self-renewal
remains to be answered, but several
possibilities can be considered. First,
cells exiting the stem cell pool generally
proliferate at a higher rate than stem
cells. Perhaps reduced FAO positions
daughter cells to be able to more readily
generate the necessary biomass for rapid
cell proliferation. Long-chain fatty acid
metabolism first involves formation of
fatty-acyl CoA in the outer mitochondrial
membrane. This fatty-acyl CoA molecule
can either contribute to the formation of
lipids or can be transferred to the mito-
chondrial matrix to undergo b-oxidation,
a process that generates acetyl-CoA enroute to ATP. Decreased FAO may be
permissive of greater lipid membrane
generation. Why might stem cells be
advantaged by increased FAO? In addi-
tion to the acetyl-CoA/ATP that is gener-
ated when FAO proceeds, there is also
generation of NADH and FADH. NADH
can serve as a proton donor for quenching
ROS, which are maintained at particularly
low levels in HSCs, presumably as a
means of protecting against DNA damage
(Jang and Sharkis, 2007). Finally, the
acetyl-CoA molecules generated by FAO
can be used as substrate for altering
histone acetylation patterns responsible
for epigenetic control of cell fate. Whether
increased acetyl-CoA facilitates preser-
vation of the stem cell epigenome is
unclear, but may be one of the elements
of the persistent change in stem cell func-
tion seen in the experiments of Ito et al.
Unraveling whether and how metabolic
parameters determine cell state is now
open for interrogation in multiple path-
ways in both malignant and normal cells.
The next generation of studies should
tell us just how sugar, fat, and fate inter-
mingle in the stem cell recipe.REFERENCES
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